Aclaris Therapeutics (ACRS) Tops Q3 EPS by 9c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.30), $0.09 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $19.02 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Redwood Trust (RWT) PT Lowered to $6.50 at UBS Amid Legacy Portfolio Wind-Down
• Why this strategist thinks longer-term outlook for stocks is "unfavorable"